Two-year outcome after biodegradable polymer sirolimus- and biolimus-eluting coronary stents (from the randomised SORT OUT VII trial)

EuroIntervention 2018;13:1587-1590 published online September 2017. DOI: 10.4244/EIJ-D-17-00731

Lisette  Okkels Jensen
Lisette Okkels Jensen1*, MD, DMSci, PhD; Michael Maeng2, MD, PhD; Bent Raungaard3, MD, PhD; Knud Nørregaard Hansen1, MD; Johnny Kahlert4, MSc; Svend Eggert Jensen3, MD, PhD; Henrik Steen Hansen1, MD, DMSci; Jens Flensted Lassen2, MD, PhD; Hans Erik Bøtker2, MD, DMSci, PhD; Evald Høj Christiansen2, MD, PhD
1. Department of Cardiology, Odense University Hospital, Odense, Denmark; 2. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; 3. Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark; 4. Department of Clinical Epide

The persistence of polymer material on first- and second-generation coronary drug-eluting stents after completion of drug release has been suggested as a trigger for a chronic

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Initial experience with the novel BioMime 60 mm-long sirolimus-eluting tapered stent system in long coronary lesions

Latest news